Feb 16 |
How Is The Market Feeling About TG Therapeutics?
|
Feb 8 |
TG Therapeutics: Inferred Expectations Point To Undervalued Shares
|
Jan 23 |
TG Therapeutics: Indications Of Slowing Market Growth For Briumvi
|
Jan 22 |
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
|
Jan 19 |
Looking Into TG Therapeutics's Recent Short Interest
|
Jan 11 |
HC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To Know
|
Jan 10 |
TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
|
Jan 10 |
TG Therapeutics Adds To Its 225% Sprint After MS Drug Crushes Sales Estimates
|
Jan 10 |
TG Therapeutics prelim results see FY23 BRIUMVI U.S. revenue $89M; initiates FY24 outlook
|
Jan 10 |
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
|